RLG Responds to Reports From Nation’s First Actos Trial
RLG is responding to reports about the first trial of more than 3,000 Actos lawsuits nationwide. In Los Angeles Superior Court, the plaintiff alleges that manufacturer Takeda Pharmaceutical Co. failed to warn doctors of the diabetes drug’s cancer risk. The Rottenstein Law Group, an Actos law firm, will monitor this trial closely as it progresses and provide updates at www.rotlaw.com/actos.
According to Bloomberg, plaintiff Jack Cooper’s doctor never received a warning from Takeda that the diabetes medication could cause bladder cancer, Cooper’s attorney asserted during open statements on Friday, Feb. 28. (In Re: Cooper v. Takeda Pharmaceuticals America Inc., CGC-12-518535; California Superior Court, Los Angeles). Cooper had taken the drug for more than four years before his 2011 cancer diagnosis.
The Rottenstein Law Group is monitoring the case via news reports and the Courtroom View Network, said Rochelle Rottenstein, principal of RLG.
“We’re hearing from people who have suffered from the alleged side effects of Actos, including its link to heart problems,” Rottenstein said. “Because it’s the first trial, it is very important. Its potential to influence future trial outcomes should not be underestimated.”
Actos went to market in 1999. By 2011, the U.S. Food and Drug Administration had issued a warning that those with a history of bladder cancer should not use Actos-type drugs. The bulk of the more than 3,000 cases are being handled in a federal pretrial consolidation called a “multidistrict litigation” in the Western District of Louisiana (MDL-2299).
